DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/8pfmw6/fanapt) has announced the addition of the "Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering.
Fanapt (iloperidone) is a D2/5-HT2A antagonist, but also has an increased activity at serotonin 5-HT7 receptors, which are believed to modulate striatal and cortical DA function. With enhanced antagonistic activity at a1 receptor sites and low activity on histamine H1 receptors, Fanapt has been associated with an issue of orthostatic hypotension (due to a1 blockade) rather than weight gain and sedation like other agents within its class.
Reasons to Buy
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
3.1 Etiology and Pathophysiology
4 Disease Management
4.2 Treatment Overview
5 Competitive Assessment
5.2 Strategic Competitor Assessment
6 Fanapt (iloperidone)
6.2 Efficacy as a Short-Term Maintenance Treatment
6.4 SWOT Analysis
For more information visit http://www.researchandmarkets.com/research/8pfmw6/fanapt
Source: Research and Markets